Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma by Ransom, M. et al.
Randomized Trial of the Combination of Lomeguatrib
and Temozolomide Compared With Temozolomide
Alone in Chemotherapy Naive Patients With Metastatic
Cutaneous Melanoma
Malcolm Ranson, Peter Hersey, Damien Thompson, Jane Beith, Grant A. McArthur, Andrew Haydon,
Ian D. Davis, Richard F. Kefford, Peter Mortimer, Peter A. Harris, Sofia Baka, Augustus Seebaran,
Ami Sabharwal, Amanda J. Watson, Geoffrey P. Margison, and Mark R. Middleton
A B S T R A C T
Purpose
To evaluate tumor response, pharmacodynamic effects, and safety of a combination of
lomeguatrib (LM), an O6-methylguanine DNA-methyltransferase (MGMT) inactivator, and
temozolomide (TMZ), TMZ alone, and LM/TMZ after disease progression on TMZ alone in
patients with advanced melanoma.
Patients and Methods
Patients with unresectable stage III or IV cutaneous melanoma who had no prior systemic
chemotherapy were randomly assigned to receive either 40 to 80 mg LM and 125 mg/m2 TMZ or
200 mg/m2 TMZ on days 1 through 5 of each 28-day treatment cycle. Drugs were administered
orally for up to six cycles of treatment. Patients on TMZ alone were offered LM/TMZ at
progression, if fit enough to receive treatment.
Results
One hundred four patients were enrolled, with 52 in each trial arm. Twenty-seven TMZ-treated
patients received LM/TMZ after progression on TMZ. Unexpectedly, analysis of tumor biopsies
showed rapid recovery of MGMT after LM/TMZ with 40 mg/d LM. Therefore, doses of LM were
escalated to 60 then 80 mg/d. Tumor response rates were 13.5% with LM/TMZ and 17.3% with
TMZ alone. No patient responded to LM/TMZ having progressed through TMZ. Median time to
disease progression was 65.5 days for LM/TMZ and 68 days for TMZ. All treatments were well
tolerated, although hematologic and gastrointestinal adverse events were common. A higher
incidence of hematological adverse events was observed in the LM/TMZ combination arm.
Conclusion
The efficacy of LM and TMZ in the current dosing schedule is similar to that of TMZ alone. To
maintain MGMT depletion in tumor dosing of LM needs to be continued beyond that of TMZ.
J Clin Oncol 25:2540-2545. © 2007 by American Society of Clinical Oncology
INTRODUCTION
Temozolomide (TMZ) is an oral methylating agent
used in the treatment of primary CNS tumors and
melanoma. Well-tolerated, it has been shown to be
at least as active as dacarbazine (DTIC), which re-
mains the standard systemic treatment for advanced
melanoma.1,2 The cytotoxicity of TMZ and DTIC
is mediated principally through methylation of
DNA at theO6 position of guanine.3-5 Repair of the
lesion by O6-methylguanine-DNA methyltrans-
ferase (MGMT) and/or tolerance based ondeficien-
cies in mismatch repair or resistance to apoptosis
have been identified as important aspects of resis-
tance to DTIC and temozolomide.6-8 Base exci-
sion repair also may bear on chemosensitivity, as
inhibition of polyadenosine diphosphate ribose
polymerase has been shown to enhance cell killing
by temozolomide.9
Tumor cells frequently express high levels of
MGMT, and preclinical studies identify the protein
as the key determinant of cell survival.5,6 Inactiva-
tion of MGMT before dosing with anO6-alkylating
agent considerably enhances the antitumor activity
of the latter drug in vitro and in animal tumor
models.6,10 Lomeguatrib (LM)—6-[4-bromo-2-
thienyl]methoxy)purin-2-amine—is a nontoxic low
molecular weight pseudosubstrate that inactivates
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MGMT. Given in combination with temozolomide, LM has been
shown to sensitize human melanoma xenografts more than can be
achieved by escalation of TMZ dose alone.11
A phase I dose escalation study conducted using the LM/TMZ
drug combination showed that intravenous (IV) administration of 10
mg/m2 LM decreased levels of MGMT in peripheral bloodmononu-
clear cells (PBMCs) and tumors bymore than 97% and 92%, respec-
tively, 4 hours after dosing. Oral administration of the same dose was
less depleting, but 40 or 80mg orally showed 100%MGMTdepletion
in PBMCs in all patients tested.12 Based on these data and tolerability,
we identified 40 mg/d LM with 125 mg/m2 TMZ given on days 1
through 5 of each 28-day cycle as the regimen for use in phase II trials.
The present study aimed to evaluate the combination of LM and
TMZ to test whether LM attenuation of MGMT activity might in-
crease the efficacy of TMZ in patients with advanced melanoma.
Besides determining tumor response rate to LM/TMZ, we aimed to
test whether the combination could produce tumor shrinkage in pa-
tients progressing on TMZ alone. Secondary objectives included as-
sessments of drug pharmacokinetics, MGMT depletion, safety, time
to progression, and survival.
PATIENTS AND METHODS
Inclusion and Exclusion Criteria
Patients with histologically proven cutaneous melanoma or unknown
primary melanoma with metastases were eligible for the study, provided they
had not received systemic chemotherapy previously. Other requirements in-
cluded stage III or IV measurable disease, age older than 18 years, Eastern
Cooperative Oncology Group performance status 0 or 1, life expectancy of
more than 12 weeks, adequate bone marrow and biochemical function (he-
moglobin 10 g/dL,WBCs 3 109/L, absolute neutrophil count 1.5
109/L, and platelets 100,000/L), creatinine 1.25 upper limit of normal
(ULN), bilirubin 1.25ULN, andAST 5 (metastases to liver) or 2ULN.
Patients were excluded if within 4 weeks of radiotherapy or immuno-
therapy; pregnant or nursing; still recovering from surgery; suffering from
significant comorbidity; and had a known CNS metastases, a history of sei-
zures, or were on antiepileptic medication.
The study was conducted in accordance with the principles of the Inter-
national Conference on Harmonisation of Good Clinical Practice guidelines
and the Declaration of Helsinki. The trial was approved by an independent
ethics committee according to national and local requirements at each trial
center. All patients gave informed, written consent.
Study Design and Statistical Considerations
The trial was a multicenter, open study in which 80 patients were to be
randomly assigned (1:1) into one of two treatment arms: LM/TMZ or TMZ
alone. Patients experiencing disease progression in the TMZ alone arm were
permitted to continue study treatment by changing to the LM/TMZ combi-
nation.The sample sizewas selectedon thebasis that 40patientswouldpermit
a satisfactory estimate of response rate for each trial arm. In addition, we
anticipated that approximately half of progressors onTMZalonewould go on
to receive combination therapy, allowing assessment of LM’s ability to reverse
resistance to TMZ.
The aim of the study was not to compare performance between the trial
arms, and descriptive statistics were generated for efficacy, toxicity, pharma-
cokinetic, andpharmacodynamic endpoints.Median time toprogression and
median survival time were estimated using Kaplan-Meier survival curves.
In the course of the trial, it became apparent that MGMT persisted in
tumor biopsy samples taken 24 to 72 hours after the end of cycle 1 LM/TMZ.
Therefore, the trial was extended by 20 patients, with the LM dose in those
assigned combination treatment being increased to 60mg/d, then to 80mg/d.
Treatment
LMenteric–coated 10-mg capsules were obtained fromKudos Pharma-
ceuticals (Kenilworth, NJ), and TMZpurchased from Schering-Plough (Wel-
wyn Garden City, United Kingdom), as 5-, 20-, 100-, and 250-mg capsules.
Patients randomly assigned to LM/TMZ received LM40mg/d orally for
5 consecutive days every 4 weeks for up to six cycles. Those among the last 20
patients randomly assigned to LM/TMZ received LM 60 mg/d or 80 mg/d.
TMZwasadministeredat 125mg/m2/dorally 2hours afterLM.Patients fasted
for 1 and 2 hours before and after TMZ and LM, respectively. On the TMZ
alonearm,patients receiveda startingdoseof200mg/m2/d, administereddays
1 through5of a 28-day cycle. Patients receivingLM/TMZafter progressing on
TMZalonewere treated as above, although theTMZdosewas adjusted to take
into account any prior dose reductions on TMZ.
A treatment delay of up to 2 weeks was allowed for resolution of drug-
related toxicity. Dose reductions in TMZweremandated in the event of grade
4hematologic toxicity, grade3 toxicity lasting7ormoredays, or anygrade3or
4 nonhematologic toxicity. These were in increments of 25 or 50 mg/m2/d
according to the treatment arm and type of toxicity encountered. A need to
reduce doses of TMZ to less than 75 mg/m2/d (LM/TMZ) or 100 mg/m2/d
(TMZ alone) required the patient to be removed from the study. Patients also
couldbewithdrawn fromthe study forprogressivedisease, serious violationof
the study drug protocol, or withdrawal of consent.
Evaluation of Response and Toxicity
All eligible patients who received any part of the treatment were consid-
ered assessable for response and toxicity. Patients were assessed for adverse
events at each attendance. Physical examination, performance status, and vital
signswere recordedat thebeginningof each treatment cycle.CBCwaschecked
before treatment and on days 14, 21, and 28, with blood chemistry tested on
days 1, 14, and 28. Adverse events were graded according to the National
Cancer Institute Common Toxicity Criteria version 2. Tumor response was
assessed every second cycle based on clinical and radiological findings in
accordance with Response Evaluation Criteria in Solid Tumors Group.
Pharmacodynamics
In a subset of patients samples for PBMCMGMT activity and/or DNA
methylation were obtained before treatment on day 1 of cycle 1 at 6 and 24
hours after dosing and once during days 5 to 8 (ie, after the end of dosing).
From 5 to 10 mL of venous blood was collected for isolation of PBMC and
analysis ofMGMT.13Where available, tumor biopsies were obtained by exci-
sion biopsy before, and up to 72 hours after completion of, the first cycle of
treatment. The biopsies were snap frozen on dry ice and stored at 80°C
before determination of MGMT activity.13 Additional pharmacodynamic
samples were drawn from patients being evaluated for pharmacokinetics at 2,
4, and 8 hours after LM administration on day 1 of cycle 1.
Pharmacokinetics
This was to be undertaken in up to eight patients receiving the
LM/TMZ combination only. Two 5mL venous blood samples were drawn
predose and at 0.5, 1, 2, 3, 4, 6, and 8 hours after dosing on days 1 and 5 of
cycle 1 to determine the LM and TMZ concentrations according to previ-
ously published methods.12,14
RESULTS
A total of 104 patients were recruited into the study, split equally into
two treatment arms (Table 1). Of the 52 patients initially treated with
TMZ alone, 27 transferred to LM/TMZ at progression. All of the
patients were assessable for safety, and all but four (three on TMZ
alone and one on LM/TMZ) for efficacy.
Four patients received drug doses significantly different from
those required by the study protocol. In all cases (one on LM/TMZ,
two on temozolomide, and one on LM/TMZ after progressing
through TMZ), doses of medication were omitted in error during
one cycle of treatment. Additionally, one patient receiving TMZ was
Lomeguatrib and Temozolomide in Melanoma
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re-treated on day 22, rather than day 29, of cycle 1. Sixteen patients
completed six cycles of treatment with LM/TMZ and nine with TMZ
alone. Most patients were withdrawn from treatment because of dis-
ease progression.
Treatment Efficacy
Responses to treatment are summarized inTable 2. Twopatients
treated with TMZ alone and one with LM/TMZ achieved complete
responses. Rates of overall response and disease stabilization were
similar for the two treatments. Stable disease was observed in 14
patients on the combination armand in 13patients on theTMZalone
arm. No patient responded to LM/TMZ having progressed through
TMZ: four patients had stable disease after two cycles, but all four
progressed before cycle 4.
Median time to disease progression was similar for the two arms
at 65.5 days for LM/TMZ (95% CI, 55 to 116 days) and 68 days for
TMZ (95% CI, 53 to 106 days). Median overall survival was 7.6
months (95%CI, 6.9 to 10.3months) and 7.7months (95%CI, 6.3 to
10.7 months), respectively.
Adverse Events
Four patients died while undergoing treatment: one on the LM/
TMZ combination and three on TMZ alone. The cause of death was
attributed to melanoma in two cases, pulmonary embolism in one
patient on TMZ, and a cerebrovascular event in an additional patient
treated with TMZ. No deaths were related to treatment.
All of the patients on the study experienced adverse events. The
pattern of these was similar for the two treatments, though an in-
creased incidence of thrombocytopenia and neutropenia was seen in
patients receiving LM/TMZ, and more vomiting was recorded in
those on TMZ alone. The most frequent treatment-related adverse
events are listed inTable 3.Patientson theLM/TMZcombinationhad
an increased incidence of grade 3 and 4 adverse events comparedwith
those on TMZ alone, but they had a lower rate of withdrawal due to
toxicity, indicating that these events were manageable. Hematologic
toxicity was more frequent when LM was administered at 60 or 80
mg/d or when LM/TMZwas administered after progression on TMZ
(Table 4).
Forty-eight patients had treatment delays: 25 patients on LM/
TMZhada total of 45dosedelays, comparedwith19patients onTMZ
who experienced 25 delays. Four more patients had delays on LM/
TMZ after progressing on TMZ. Twenty-four of the treatment delays
onLM/TMZwere causedby grade 3or 4hematologic toxicity, aswere
the majority of the delays in patients on the combination having
progressed through TMZ. Ten out of 25 delays on TMZwere caused
by hematologic toxicity. Most other delays were for logistic reasons,
such as awaiting scan results. Twenty patients on LM/TMZ required
dose reductions in TMZ, compared with seven on TMZ alone. In all
but two cases, reductions were made for hematologic toxicity.
Pharmacodynamics
MGMTactivity in PBMCs fellmore rapidly and completelywith
combination therapy than with TMZ alone. At 4 and 22 hours after
TMZdosing patients on LM/TMZhadnodetectableMGMTactivity,
whereas all but one TMZ-treated patient had residual activity (Table
5). Tumor biopsies were obtained on days 6 through 8 of cycle 1 in
nine patients on LM/TMZ at 40mg/d LM and in five on TMZ alone.
Unexpectedly, given the more than 92% depletion of MGMT ob-
served after a single LM dose in the phase I trial, residual MGMT
activity was detected in five of the nine LM/TMZ patients’ samples
(0.7, 0.8, 1.5, 1.6, and 4.5 fmol/g DNA). Two of the five samples
taken after TMZ treatment had detectable MGMT (2.3 and 2.8
fmol/gDNA). Four patients who received LMdose at 60 or 80mg/d
underwent tumor biopsies on day 6, and residualMGMTactivity was
detectable in three of these cases. In four further patients, tumor
biopsies were obtained on day 5, a few hours after the final dose of
TMZ, and no residual MGMT activity could be detected.
Pharmacokinetics
Samples were obtained from seven patients, but in two cases, the
profiles were incomplete. Both drugs had similar pharmacokinetic
parameters on days 1 and 5 of administration (Table 6).
DISCUSSION
The results of this study do not support the hypothesis that clinical
inactivation of MGMT enhances the activity of TMZ in melanoma.
Weobserved similar antitumor activity in the two treatment arms and
no reversal of resistance to TMZ with the addition of LM. The
response rate of 13.5%with combination therapy is disappointing,
as it represents no improvement on that seen in the phase II
Table 1. Patient Characteristics at Random Assignment
Characteristic LM/TMZ (n  52) TMZ (n  52)
Age, years
Median 56 57
Range 32 to 82 21 to 82
Sex
Male 33 36
Female 19 16
Disease status
Stage 3 2 1
M1a 4 3
M1b 16 15
M1c 30 33
ECOG PS
0 32 27
1 19 24
Missing 1 1
Prior therapy
Immunologic/biologic 15 14
Radiation 22 15
Abbreviations: LM, lomeguatrib; TMZ, temozolomide; ECOG PS, Eastern
Cooperative Oncology Group performance status.
Table 2. Best Response by Treatment Arm
Response
LM/TMZ
(n  52)
TMZ
(n  52)
LM/TMZ on
Progression
(n  27)
Complete response 1 2 0
Partial response 6 7 0
Stable disease 14 13 4
Progressive disease 30 28 22
Not evaluated 1 2 1
Response rate, % 13.5 17.3 0
Abbreviations: LM, lomeguatrib; TMZ, temozolomide.
Ranson et al
2542 JOURNAL OF CLINICAL ONCOLOGY
Downloaded from ascopubs.org by University of Queensland on February 9, 2017 from 130.102.082.116
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
comparison of TMZ and dacarbazine, a trial with similar entry
criteria to the current study.13
The patients treated with TMZ alone had response rates,
median survival, and toxicity similar to those reported in previous
large studies.1,13 The combination of LM and TMZ used in this
study also was well tolerated. Hematologic toxicity was more fre-
quent, but readily managed, and nonhematologic adverse effects
were very similar to those seen with the methylating agent alone.
Higher doses of LM appeared to result in greater myelotoxicity, an
interesting finding given the total depletion of MGMT in PBMCs
during the first day of treatment at the 40-mg dose level. PBMCs
may not be as good a surrogate for bonemarrow progenitor cells as
previously thought.14 Alternatively, the dose of LM may have in-
fluenced the duration, rather than the extent, of depletion, and this
may have influenced the degree ofmyelosuppression observed. No
new LM-specific toxicity was encountered.
The TMZ-treated group was included in the trial design for two
reasons. We wished to check that our patient population behaved
similarly to those treated with the drug in previous studies, and this
proved to be the case. We also wished to test the hypothesis that the
Table 3. Most Common Treatment-Related Toxicities
Event
LM/TMZ (n  52) TMZ (n  52)
LM/TMZ on Progression
(n  27)
No. % No. % No. %
All adverse events
Thrombocytopenia 24 46 14 27 18 67
Neutropenia 27 52 5 10 17 63
Febrile neutropenia 5 10 2 4 4 15
Anemia 8 15 5 10 5 19
Nausea 37 71 36 69 11 41
Vomiting 11 21 17 33 4 15
Constipation 8 15 10 19 6 22
Diarrhea 3 6 5 10 1 4
Dyspepsia 4 8 2 4 0 0
Fatigue 18 35 22 42 8 30
Pyrexia 3 6 4 8 0 0
Anorexia 11 21 15 29 5 19
Headache 5 10 9 17 5 19
Alopecia 3 6 0 0 1 4
Serious adverse events
Thrombocytopenia 5 10 2 4 5 19
Neutropenia 13 25 1 2 12 44
Febrile neutropenia 4 8 2 4 4 15
Anemia 2 4 5 10 0 0
Nausea 3 6 1 2 1 4
Vomiting 3 6 2 4 0 0
NOTE. Adverse events considered possibly, probably, or highly probably related to treatment occurring in 5% or more patients in any study arm.
Abbreviations: LM, lomeguatrib; TMZ, temozolomide.
Table 4. Treatment-Related Hematologic Toxicity on LM/TMZ
Event
40 mg/d First Line
(n  42)
60 to 80 mg/d First
Line (n  10)
40 mg/d
Progression
(n  22)
60 to 80 mg/d
Progression (n  5)
No. % No. % No. % No. %
All adverse events
Thrombocytopenia 17 41 7 70 13 59 5 100
Neutropenia 19 45 8 80 12 55 5 100
Febrile neutropenia 2 5 3 30 3 14 1 20
Anemia 6 14 2 20 4 18 1 20
Serious adverse events
Thrombocytopenia 5 12 2 20 4 18 1 20
Neutropenia 9 21 4 40 9 41 3 60
Febrile neutropenia 2 5 2 20 3 14 1 20
Anemia 1 2 1 10 0 0 0 0
Abbreviations: LM, lomeguatrib; TMZ, temozolomide.
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inactivation of MGMT could reverse melanoma resistance to TMZ
treatment. Just more than half of the patients from the TMZ arm
receivedcombination treatmentonprogression,butnoneachievedan
objective response. In two instances, patients exhibited shrinkage in
individual tumor deposits that had previously been growing, but in
neither case was there a significant decrease in the overall tumor
burden. If reversal of resistance can occur, it does not appear to be a
frequent occurrence, on the basis of our results.
The pharmacokinetics of LM and TMZ were assessed in a
small number of patients. It is not possible to compare the results
directly for LMwith those from the phase I trial, as the formulation
used here was different and there are only very limited data from
the earlier study for the oral administration of the doseweused.We
found no evidence that coadministration of LM affected TMZ
pharmacokinetics, in that the parameters were comparable to
those previously published, taking into account the lower dose
used in this study.13
There are several possible reasons why MGMT inhibition
failed to enhance the efficacy of TMZ in our trial. Inactivation of
the protein in normal as well as tumor tissue necessitates a reduc-
tion in the dose of the accompanying chemotherapy. The relative
overexpression of MGMT in tumor tissue should mean that a gain
in therapeutic index, as seen in animal models,11 can be achieved.
In practice, this did not occur, perhaps because of greater accessi-
bility of the drug to bonemarrow. Some targeting of drug to tumor
may be required to realize the benefits of DNA repair inhibition.
Likewise, the combination of O6-benzylguanine with carmustine
requires that the dose of the latter agent is reduced and that en-
hanced activity has not been observed.15
MGMT may not be critical to cell survival after O6-alkylating
agent therapy, at least in certain clinical situations, because other
factors ensure that damage is tolerated rather than resulting in cell
death.Even though there is extensivepreclinical evidence thatMGMT
is important in determining cellular sensitivity tomethylating agents,
in the clinic, a clear relationship between protein level and response to
treatment has only been shown for primary CNS tumors. Here, low
MGMT expression (or hypermethylation of the gene promoter) has
been linkedwith improvedsurvivaloran increasedchanceof response
to O6-alkylating agent treatment in a number of trials .16-18 In mela-
noma, we failed to demonstrate a relationship between pretreatment
tumorMGMTand clinical outcomewith TMZ,19 though others have
suggested that the probability of a response to DTIC increases with
reducing amounts of tumor MGMT.20 It is interesting to note that
where responses to DNA damage are intact, such as in bone marrow
progenitor cells, pretreatmentMGMTconcentration is a goodpredic-
tor of cell survival.21
It may be that we have not adequately tested the premise that
MGMT inactivation enhances TMZ activity. We found residual
protein activity in tumor biopsies taken 24 to 72 hours after the end
of the first treatment cycle. This was not expected, for we observed
complete inactivation of MGMT after a single dose of LM in three
of five patients in the phase I trial of LM/TMZ and more than
96% in the other two cases.12 Pharmacodynamic measures from
the current study show that MGMT recovers rapidly after treat-
ment with LM/TMZ. This finding is significant in that O6-
methylguanine is toxic only through replication and may be
repaired effectively at any point beforehand.3 The presence of
MGMT soon after dosing suggests that repair of potentially cyto-
toxic lesions is taking place and, hence, that a longer period of LM
administration is needed.
Coadministration of LM and TMZ for 5 days is well tolerated,
but it has efficacy similar to TMZ alone. LM dosing should be
Table 6. Pharmacokinetics of Lomeguatrib and Temozolomide
Day 1 Day 5
Drug Mean SD Mean SD
Lomeguatrib, n  5
Vz/F, L 1,025.0 775.3 1,319.0 771.3
CL/F, L/h 555.3 469.6 582.1 362.0
AUClast, h  ng/mL 83.34 61.73 85.03 52.81
T1/2 1.35 0.277 1.81 0.941
Temozolomide, n  5
Vz/F, L 37.70 16.53 34.01 10.64
CL/F, L/h 13.74 7.156 12.91 3.550
AUClast, h  g/mL 15.76 4.128 16.45 2.348
T1/2 1.96 0.230 1.81 0.123
Abbreviations: SD, standard deviation; Vz, volume of distribution, terminal phase; F, bioavailability; CL, clearance; AUClast, area under the serum concentration-time
curve up to the last sampling; T1/2, terminal half-life.
Table 5. MGMT Concentration in PBMCs on the First Day of Treatment
Mean MGMT (fmol/mg
DNA  SEM) LM/TMZ TMZ
LM/TMZ
Progression
Pretreatment 16.5  1.68 16.8  1.69 9.5  1.49
No. 28 28 7
6 hours 0 14.8  2.37 0
No. 27 25 6
24 hours 0 12.5  1.41 0
No. 26 26 6
Day 6 or 7 0.62  0.28 0.83  0.83 0.5  0.5
No. 5 3 3
NOTE. Only data from patients treated with lomeguatrib 40 mg/day
are presented.
Abbreviations: MGMT, O6-methylguanine DNA-methyltransferase; PBMC,
peripheral blood mononuclear cells; LM, lomeguatrib; TMZ, temozolomide.
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continued beyond that of TMZ to maintain MGMT inactivation.
Such a combination will test whether repair protein depletion can
improve the outcome for patients, and a trial with this design in
melanoma is under way.
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